Patient leaflet - Tauvid 1 900 MBq/ml solution for injection
1. What Tauvid is and what it is used for
This medicine is a radiopharmaceutical product for diagnostic use only.
Tauvid is given to adults with memory problems so that doctors can perform a type of brain scan, called a PET (Positron Emission Tomography) scan. Tauvid, along with other brain function tests, may help your doctor find the reason for your memory problems. Tauvid can help your doctor determine whether or not you may have abnormal forms of tau protein in your brain. Abnormal forms of tau protein are present in the brains of people with Alzheimer’s disease. You should discuss the results of the test with the doctor that requested the scan.
The use of Tauvid does involve exposure to amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweighs the risk due to radiation.
2. What you need to know before Tauvid is used
Tauvid must not be used
if you are allergic to flortaucipir (18F) or any of the other ingredients
of this medicine (listed in section 6).
Warnings and precautions
Take special care with Tauvid
- if you have liver or kidney problems
- if you are pregnant or believe you may be pregnant
- if you are breast-feeding
Children and adolescents
Tauvid is not intended for use in children and adolescents.
Other medicines and Tauvid
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given this medicine.
You must inform the nuclear medicine doctor before the administration of Tauvid if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding. When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.
If you are pregnant
The nuclear medicine doctor will only administer this product during pregnancy if a benefit is expected which would outweigh the risks.
If you are breast-feeding
You must stop breast-feeding for 24 hours after the injection and the maternal milk pumped must be discarded. Please ask your nuclear medicine doctor when you can resume breast-feeding. See section 3 for information related to close contact with infants following injection.
Driving and using machines
It is considered unlikely that Tauvid will affect your ability to drive or to use machines.
Tauvid contains ethanol
This medicine contains 790 mg of alcohol (ethanol) in each 10 mL dose, which is equivalent to 11.3 mg/kg (administered to an adult with 70 kg). The amount in 10 mL of this medicine is equivalent to less than 20 mL beer or 8 mL wine. The small amount of alcohol in this medicine will not have any noticeable effects.
Tauvid contains sodium
Tauvid 800 MBq/mL solution for injection contains up to 32 mg sodium (main component of cooking / table salt) in each dose. This is equivalent to 1.6 % of the recommended maximum daily dietary intake of sodium for an adult.
Tauvid 1 900 MBq/mL solution for injection contains up to 34 mg sodium (main component of cooking / table salt) in each dose. This is equivalent to 1.7% of the recommended maximum daily dietary intake of sodium for an adult.
3. How Tauvid is used
There are strict laws on the use, handling and disposal of radiopharmaceutical products. Tauvid will only be used in special controlled areas. This product will only be handled and given to you by people who are trained and qualified to use it safely. These persons will take special care for the safe use of this product and will keep you informed of their actions.
Package leaflet: Information for the patient
Tauvid® 800 MBq/mL solution for injection Tauvid® 1 900 MBq/mL solution for injection
flortaucipir (18F)
N/A
The nuclear medicine doctor supervising the procedure will decide on the quantity of Tauvid to be used in your case. It will be the smallest quantity necessary to get the desired information. The usual amount recommended for an adult is 370 MBq. Megabecquerel (MBq) is the unit used to express radioactivity.
Administration of Tauvid and conduct of the procedure
Tauvid is administered as an injection into your vein (intravenous injection) followed by a flush of sodium chloride solution to ensure full delivery of the dose.
One injection is sufficient to conduct the test that your doctor needs.
Duration of the procedure
Your nuclear medicine doctor will inform you about the usual duration of the procedure. A brain scan lasts 20 minutes and is usually taken from about 80 to 100 minutes after the Tauvid injection is given.
After administration of Tauvid, you should:
Avoid any close contact with young children and pregnant women
for 4 hours following the injection (see section 2).
The nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medicine. Contact your nuclear medicine doctor if you have any questions.
If you have been given more Tauvid than you should
An overdose is unlikely because you will only receive a single dose of Tauvid precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the case of an overdose, you will receive the appropriate treatment.
Should you have any further question on the use of Tauvid, please ask the nuclear medicine doctor who supervises the procedure.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects of Tauvid are uncommon (may affect up to 1 in 100 people):
- headache
- altered taste
- pain where the injection is given
- blood pressure increase
This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities. See section 1.
Reporting of side effects
If you get any side effects talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
5. How Tauvid is stored
You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.
The following information is intended for the specialist only. Tauvid must not be used after the expiry date which is stated on the shield and vial label after EXP.
Tauvid must not be administrated if particulate matter or discolouration is noticed.
6. Contents of the pack and other information
What Tauvid contains
The active substance is flortaucipir (18F).
Tauvid 800 MBq/mL solution for injection: 1 mL of solution for injection contains 800 MBq of flortaucipir (18F) at the date and time of calibration. The other ingredients are anhydrous ethanol, sodium chloride, water for injections (see section 2 “Tauvid contains ethanol” and “Tauvid contains sodium”).
Tauvid 1 900 MBq/mL solution for injection: 1 mL of solution for injection contains 1 900 MBq of flortaucipir (18F) at the date and time of calibration. The other ingredients are anhydrous ethanol, dibasic sodium phosphate, hydrochloric acid, sodium chloride, water for injections (see section 2 “Tauvid contains ethanol and sodium”).
What Tauvid looks like and contents of the pack
Tauvid is a clear, colourless solution for injection. It is supplied in a 15 mL clear glass vial.
Tauvid 800 MBq/mL solution for injection: One multidose vial of 15 mL capacity containing 1 to 15 mL of solution, corresponding to 800 to 12 000 MBq at date and time of calibration.
Tauvid 1 900 MBq/mL solution for injection: One multidose vial of 15 mL capacity containing 1 to 15 mL of solution, corresponding to 1 900 to 28 500 MBq at date and time of calibration.
Marketing Authorisation Holder
Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, The Netherlands.
Manufacturer
For information on the manufacturer, see vial and shield label.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
United Kingdom
Eli Lilly and Company Limited
Tel: + 44-(0) 1256 315000
This leaflet was last revised in March 2026
------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:
The complete SmPC of Tauvid is provided in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical. Please refer to the SmPC [SmPC should be included in the box].
N/A